Dr. Daewoong Jo has devoted more than 20 years of his life toward developing the macromolecule intracellular transduction technology (MITT) platform, a technique that can deliver protein-based therapies into cells and tissues, including the brain, by crossing the blood-brain barrier (tissues that protect the brain from harm). During his doctoral studies at Vanderbilt University in Nashville, USA, post-doctoral fellowships at both Sager Institute in Hixtone, UK and Vanderbilt University and professional work at Chonnam National University in Kwangju, Korea, ProCell Therapeutics, Inc. in Seoul, Korea, and Cellivery Therapeutics, Inc. in Seoul, Korea, Dr. Jo has contributed to the development of enzymes (Cre recombinase, SB transposase and Cas9 nuclease) and therapies (SOCS3, Nm23, p53, p18, RUNX3, Endostatin, iPSC reprogramming factors, BMP2, Parkin and others) that can pass through cells and proteins by utilizing the MITT platform. In 2014, Dr. Jo published a paper on cell-permeable (CP) Parkin (protein encoded by the PARK2 gene that is linked to Parkinson's), which could be used to help correct Parkin levels in those with Parkinson's disease (PD) by promoting cell survival and improving motor function. Since then, Dr. Jo has optimized the cell-permeable Parkin, known as iCP-Parkin. iCP-Parkin treatment has been shown to significantly restore PD symptoms in several pre-clinical models.